Post COVID-19 Patients Experience Lingering Muscle Aches, Back Pain, Coughing, Poor Digestion; Bioelectronic Relief From Chronic Pain Offered By Electromedical Technologies, Inc. (OTCQB: EMED) Through Devices That Are Alternative To Opioid Addicting Pain Killer Pharmaceuticals
Dr. Anthony Fauci warns about post-viral syndrome for patients that have survived COVID-19. Some are experiencing recurring back pain, muscle aches, digestive issues and even fatigue and what he calls ‘brain fog.’ These patients lived through COVID-19 and now have a choice to make: should they return to possibly opioid-addicting, pain killer pharmaceutical drugs. Electromedical Technologies, Inc. (OTCQB: EMED) offers a solution in non-opioid, non-pharmaceutical drugs bioelectronic relief through its growing line of FDA-cleared WellnessPro Plus™ devices that deliver electrotherapy treatment for chronic and acute pain.
The chronic pain treatment market has drawn intense interest from media companies. stockmarketpress.com features specialized coverage of related stocks such as Electromedical Technologies, Inc. (OTCQB: EMED), Medtronic PLC (NYSE: MDT), Nevro Corp. (NYSE: NVRO), Axsome Therapeutics, Inc. (NASDAQ: AXSM). GlaxoSmithKline (NYSE: GSK), Abbott Laboratories (NYSE: TBA), Eli Lilly (NYSE: LLY), Boston Scientific Corporation (NYSE: BSX), Novartis AG (NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).
Post COVID-19 Patients Experience Lingering Muscle Aches, Back Pain, Coughing, Poor Digestion; Bioelectronic Relief From Chronic Pain Offered By Electromedical Technologies, Inc. (OTCQB: EMED) Through Devices That Are Alternative To Opioid Addicting Pain Killer Pharmaceuticals
After living through COVID-19, patients may be warned by their physicians about post-recovery back pain, muscle aches, digestive issues, coughing and other factors. Some patients wish to avoid opioid addiction by not returning to pain killer pharmaceuticals. Physicians refer to these post-COVID-19 patients as ‘long-haulers.’ Electromedical Technologies, Inc. (OTCQB: EMED) has developed devices such as the FDA-cleared WellnessPro Plus™ and anticipated for 2021 the WellnessPro® Pod. These are non-invasive and avoid side-effects such as opioid addiction.
Dr. Fauci Sees A ‘Post-Viral Syndrome’
Dr. Fauci, Director of the National Institute of Allergy and Infectious Diseases and member of the White House Coronavirus Task Force, calls these post COVID-19 issues a post-viral syndrome. This can create lingering, significant pain in patients who have already successfully survived the pandemic.Long-haul patients are frustrated by the gap in treatments for post-COVID-19 pain — and their treatment providers concur. Healthline describes the pain these patients endure. The medical world sees these recurring issues and in this pandemic must treat sufferers without leading them any addiction.
Bioelectronic Treatment Offers Pain Relief
Electromedical Technologies, Inc. (OTCQB: EMED) is a leader in the field of addressing acute and chronic pain and sees itself at the forefront of future medicine. Opioid addiction from pain-killer pharmaceuticals, is only made worse by COVID-19. The global pandemic causes patients with chronic pain to limit or avoid physical physician visits, postpone surgical treatments and limit out-of-home mobility. StreetInsider.com describes how electrotherapy and bioelectronic treatments can be helpful in treating chronic and acute pain without addictive drugs. It terms the Electromedical Technologies, Inc. (OTCQB: EMED) devices as in the forefront of the future of medicine.
Financial Express finds that the post COVID-19 pain can also extend to digestive issues, causing loss or increased appetite, upper abdominal pain diarrhea and vomiting. These, combined with the back pain and muscle cramps and other issues, makes medical treatment to treat pain with non-addictive pain killers an important matter.
Post COVID-19 Patients Experience Lingering Muscle Aches, Back Pain, Coughing, Poor Digestion; Bioelectronic Relief From Chronic Pain Offered By Electromedical Technologies, Inc. (OTCQB: EMED) Through Devices That Are Alternative To Opioid Addicting Pain Killer Pharmaceuticals.
Pain Treatment Is Seen As A Market To Reach $ 151.7 Billion By 2030
A new research study by The Centers For Disease Control And Prevention (CDC) finds that greater than 20% of American adults suffer from chronic pain and high-impact chronic pain, sometimes resulting in opioid dependence. The COVID-19 pandemic, a recent study by Prescient & Strategic Intelligence reports, only exacerbates these numbers and will help drive the chronic pain treatment market globally by a 6.5% CAGR rate to $151.7 Billion by 2030 from $77.8 Billion in 2019. The report finds that North America dominates the global chronic pain market. Medical firms such as Electromedical Technologies, Inc. (OTCQB: EMED) offer alternative treatments. EMED also collaborates with Universities and Schools on researching the chronic pain market and treatments. Post COVID-19 Patients Experience Lingering Muscle Aches, Back Pain, Coughing, Poor Digestion; Bioelectronic Relief From Chronic Pain Offered By Electromedical Technologies, Inc. (OTCQB: EMED) Through Devices That Are Alternative To Opioid Addicting Pain Killer Pharmaceuticals.
Coming Next Year: The Wearable WellnessPro® Pod
Electromedical Technologies, Inc. (OTCQB: EMED) offers a growing line of devices that deliver electrotherapy treatment for chronic and acute pain. Next year, the Company anticipates bringing to market its WellnessPro® Pod. The Company is collaborating with numerous universities and schools to research the field of bioelectronics. It is seeking to develop a program to study the effects of electro-modulation on the human body, especially cell signaling and virus assembly and immune responses. The WellnessPro Plus™ is a non-invasive device designed to avoid painkiller pharmaceuticals and opioid addiction
Source: Stock Market Press
Join Stock Market Press’ newsletter for the latest in IPO, market commentary and company profiles.
Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.
Contact:
Stock Market Press
110 Wall St.
New York, NY 10005 info@stockmarketpress.com Safe Harbor Statement:
Statements in this news release may be ”forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.
See Stock Market Press disclaimer: https://stockmarketpress.com/disclaimer/ SOURCE: Stock Market Press
